Form 4: Liquidia CHRO Sarah Krepp Granted Equity Awards

Liquidia Corp's Chief Human Resource Officer, Sarah Krepp, received grants of Restricted Stock Units and Performance Stock Units on January 16, 2026.

Summary

• Sarah Krepp, Chief Human Resource Officer of Liquidia Corp (LQDA), was granted 23,728 Restricted Stock Units (RSUs) on January 16, 2026.
• These RSUs convert into common stock on a one-for-one basis and have a vesting schedule of 25% on January 11, 2027, followed by 6.25% every three months thereafter.
• Additionally, Ms. Krepp was granted 35,592 Performance Stock Units (PSUs) on January 16, 2026, which also convert into common stock on a one-for-one basis.
• The PSUs vest upon a time-based schedule (25% on January 11, 2027, or the FY2026 10-K filing date, then 6.25% every three months) contingent on achieving a milestone-based vesting condition related to net product sales revenue from YUTREPIA in 2026.
• Following these transactions, Ms. Krepp beneficially owns 164,497 shares of common stock (including vested and unvested RSUs and ESPP shares) and 35,592 PSUs.
• Her total beneficial ownership includes previously granted unvested RSUs: 29,482 from January 11, 2024; 7,787 from July 1, 2024; 38,145 from January 11, 2025; and 25,000 from July 1, 2025, none of which had vested as of the filing date for the latter two grants.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation grants to a key executive, which is a positive for aligning management incentives with company performance, particularly YUTREPIA sales. It does not contain information that would significantly alter the company's fundamental outlook, hence a moderately positive sentiment.

Positives

• The equity grants (RSUs and PSUs) align the Chief Human Resource Officer's interests with those of shareholders, incentivizing long-term company performance.
• The performance-based vesting condition for PSUs, tied to YUTREPIA net product sales revenue in 2026, directly links executive compensation to a key product's commercial success.

Risks

• The vesting of 35,592 Performance Stock Units is contingent upon achieving specific net product sales revenue from YUTREPIA in 2026, as disclosed in the Issuer's FY2026 10-K. Failure to meet this milestone could result in forfeiture of these units.

Future Outlook

The performance-based vesting of PSUs on YUTREPIA net product sales revenue in 2026 indicates a strategic focus on the commercial success of this product and aligns executive incentives with its performance.

Industry Context

Equity grants, including both time-based Restricted Stock Units and performance-based Performance Stock Units, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. This practice aims to align the interests of executives with long-term shareholder value creation, often by tying a portion of compensation to specific product milestones or financial performance metrics, such as sales revenue for key drugs like YUTREPIA.

Comparison to Industry Standards

• The structure of executive compensation, incorporating both time-based RSUs and performance-based PSUs, is consistent with common practices observed across the biotechnology and pharmaceutical sectors.
• Tying PSU vesting to specific product sales revenue (YUTREPIA in 2026) is a typical mechanism to incentivize the commercial success of critical pipeline assets, similar to how other companies link executive bonuses to drug approval milestones or market penetration targets.

Related Party Transactions

• The grants of Restricted Stock Units and Performance Stock Units to Sarah Krepp, the Chief Human Resource Officer, constitute related party transactions as they involve compensation to a key management personnel.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with shareholder value creation, particularly through the performance-based component tied to YUTREPIA sales.
• Employees (specifically the CHRO): Sarah Krepp receives significant equity compensation, which serves as an incentive and a component of her overall remuneration package.

Next Steps

• Vesting of 23,728 RSUs will commence on January 11, 2027, with 25% vesting initially, followed by 6.25% every three months.
• Vesting of 35,592 PSUs will commence on January 11, 2027 (or the FY2026 10-K filing date, if later), with 25% vesting initially, followed by 6.25% every three months, contingent on YUTREPIA net product sales revenue in 2026.

Key Dates

Recommendation

This Form 4 reports routine equity compensation grants to a key executive, aligning their interests with the company's long-term performance, particularly regarding YUTREPIA sales. While positive for incentive alignment, it does not provide new fundamental information to significantly alter an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Liquidia Corp, LQDA, Form 4, insider transaction, equity grant, RSU, PSU, restricted stock units, performance stock units, executive compensation, Sarah Krepp, YUTREPIA